STOCK TITAN

Becton Dickinson & Co - BDX STOCK NEWS

Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.

Overview

Becton, Dickinson and Company (BD) is a global medical technology enterprise with decades of expertise in developing, manufacturing, and distributing an extensive range of medical supplies, devices, and diagnostic products. By combining innovation with operational excellence, BD provides critical solutions that are central to patient care, medical discovery, and diagnostic accuracy. Keywords such as medical discovery, diagnostic solutions, and clinical efficiency serve as a testament to its commitment to advancing healthcare across the globe.

Business Model and Core Operations

BD operates through a diversified business model that spans three key segments:

  • BD Medical: Focused on the development and manufacturing of essential surgical products such as needles, syringes, sharps-disposal units, prefilled drug delivery systems, and medication management solutions.
  • BD Life Sciences: Provides state-of-the-art diagnostic instruments, laboratory equipment, reagents, and flow cytometry systems essential for clinical diagnostics and research applications.
  • BD Interventional: Specializes in innovative interventional devices and systems that support surgical procedures and advanced patient monitoring.

The company generates revenue by designing high-quality products for healthcare institutions, physicians, and researchers worldwide, ensuring that each solution meets the rigorous demands of clinical environments and laboratory settings.

Market Position and Competitive Landscape

Positioned as a major player in the medical technology industry, BD stands out for its robust portfolio and widespread market presence. Its commitment to quality, backed by stringent manufacturing and regulatory standards, ensures that its products remain at the forefront of healthcare innovation. In a competitive landscape, BD leverages its diverse product lines and deep industry expertise to address both mature markets and emerging growth areas, balancing reliability with technological advancement.

Technological Innovation and Quality Assurance

Innovation lies at the heart of BD’s operations. The company consistently integrates automation, robotics, and advanced digital technologies into its product lines to enhance workflow efficiency and diagnostic precision. Technological innovation is coupled with rigorous quality assurance processes that adhere to international regulatory standards, ensuring that every product provides reliable performance and safety in critical healthcare settings.

Global Reach and Operational Excellence

With manufacturing facilities and distribution networks spanning multiple countries, BD maintains a resilient supply chain that supports its global operations. A significant emphasis on domestic manufacturing reinforces the stability and reliability of essential medical products, ensuring that healthcare providers receive consistent support and that production remains robust amid industry challenges.

Conclusion

Becton, Dickinson and Company embodies the principles of innovation, quality, and operational excellence in the medical technology industry. Its comprehensive portfolio—from surgical supplies and diagnostic instruments to advanced interventional devices—demonstrates a commitment to enhancing clinical outcomes and supporting medical professionals around the world. This detailed overview reflects BD’s unwavering dedication to advancing healthcare and underscores its significant role in global patient care and medical research.

Rhea-AI Summary

BD (Becton, Dickinson and Company) will be presenting at the Bank of America Securities Health Care Conference 2024 on May 14, 2024. The presentation will be live-streamed on BD's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
conferences
-
Rhea-AI Summary
Revelyst appoints Joe Beck as Chief Supply Chain Officer to lead business transformation and efficiency efforts. Beck brings extensive experience in global supply chain operations and logistics, with a proven track record of success. His strategic vision aligns with Revelyst's goal of becoming the industry's top brands house, driving growth and innovation. Beck's appointment signals a pivotal moment for Revelyst as it restructures its business model and invests in high-potential brands for accelerated growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary
BD (Becton, Dickinson and Company) receives the Business Group on Health 'Best Employers: Excellence in Health & Well-being Award' for its commitment to employee well-being. The company also earns honors for 'Excellence in Global Health & Well-being' for its diverse benefits offerings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
Rhea-AI Summary
BD announces the global commercial release of the new BD FACSDiscover™ S8 Cell Sorters featuring BD CellView™ Image Technology and BD SpectralFX™ Technology, offering breakthrough innovations in real-time imaging and spectral flow cytometry. Researchers in various fields can now access greater flexibility and options to incorporate this technology in their labs, enabling them to confirm complex biological insights, obtain individual cell images, and isolate desired cells based on visual characteristics at high speeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
-
Rhea-AI Summary
BD (Becton, Dickinson and Company) will report financial results for its second quarter of fiscal year 2024 on May 2, 2024. The news release will include summary financial information for the quarter ending on March 31, 2024. BD management will host an audio webcast to discuss financial results, operations, and strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
-
Rhea-AI Summary
BD (Becton, Dickinson and Company) unveils survey results revealing patient concerns over repetitive needlesticks during hospital procedures. The survey, conducted by The Harris Poll, shows that many Americans are unaware of the risks associated with common medical procedures, with over half fearing multiple needle insertions. Nurses also express concerns over the negative impact of repeated needlesticks on patient care delivery and workflow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
none
Rhea-AI Summary
BD (Becton, Dickinson and Company) has been recognized for its innovation by being named to Fortune's 2024 list of America's Most Innovative Companies. This acknowledgment highlights BD's commitment to driving advancements in medical technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
none
-
Rhea-AI Summary
BD (Becton, Dickinson and Company) responds to the FDA Safety Communication regarding plastic syringes by increasing U.S. production to meet demand. The company assures the safety and quality of its products, emphasizing its commitment to supporting the healthcare system and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
Rhea-AI Summary
BD (Becton, Dickinson and Company) partners with Danish health care institutions to recycle used blood collection tubes, reducing environmental impact. The innovative method involves cleaning and recycling PET plastic tubes, diverting 33 tonnes of plastic from incineration annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
News
Rhea-AI Summary
Zeus, a leading polymer extrusion and catheter design manufacturer, appoints Padraic 'Paddy' O'Brien as the new CEO. O'Brien, currently the Worldwide President of BD Peripheral Intervention, brings a wealth of experience to lead Zeus under EQT ownership. The company aims for growth and innovation in the medical device industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none

FAQ

What is the current stock price of Becton Dickinson & Co (BDX)?

The current stock price of Becton Dickinson & Co (BDX) is $198.71 as of April 18, 2025.

What is the market cap of Becton Dickinson & Co (BDX)?

The market cap of Becton Dickinson & Co (BDX) is approximately 57.1B.

What are BD's core business segments?

BD operates in three main segments: BD Medical, BD Life Sciences, and BD Interventional, offering a range of products from surgical supplies to diagnostic instruments.

How does BD generate its revenue?

BD generates revenue by developing, manufacturing, and distributing high-quality medical devices and diagnostic products, serving healthcare providers, research institutions, and laboratories globally.

Who are the primary customers of BD?

BD’s products are utilized by hospitals, health systems, physicians, laboratory professionals, and life science researchers to support clinical treatments and diagnostic tests.

How does BD ensure the quality and safety of its products?

BD adheres to stringent quality assurance protocols and international regulatory standards, ensuring that all products meet high safety and performance criteria.

What distinguishes BD in the competitive medtech market?

BD's diverse portfolio, continuous innovation in product design, and robust global manufacturing and distribution capabilities set it apart from competitors.

How is technology integrated into BD’s product development?

The company incorporates cutting-edge automation, robotics, and digital technologies into its equipment and diagnostic tools, enhancing efficiency and accuracy in clinical applications.

What role does global manufacturing play in BD's success?

A strong global manufacturing network ensures a resilient and reliable supply chain, allowing BD to consistently meet the demand for essential medical products around the world.

How does BD support healthcare providers?

BD collaborates with healthcare organizations to tailor solutions that improve clinical outcomes, streamline workflows, and enhance overall patient care across various settings.
Becton Dickinson & Co

NYSE:BDX

BDX Rankings

BDX Stock Data

57.06B
285.49M
0.56%
93.73%
1.02%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
FRANKLIN LAKES